【摘要】 综述近年来抗肝纤维化药物研究的概况。肝纤维化是持续的慢性损害所致的肝脏细胞外基质(ECM)过度沉积和组织结构重构的病理变化,肝星状细胞(HSCs)的活化为其发生的关键环节。不断阐明的肝纤维化分子机制使抗肝纤维化药物研究有了长足进步。目前,抗肝纤维化药物主要包括肝细胞保护剂、ECM合成降解调节剂、HSCs活化凋亡调节剂、抗炎免疫调节剂。中医药治疗肝纤维化研究也取得了一定的进展。更多还原

【Abstract】 This recent progress in the research of anti-fibrotic drugs in recent years was reviewed.Hepatic fibrosis,resulted from sustained chronic liver injuries,is a pathological change characterized by the excessive accumulation of extracellular matrix(ECM) including collagen and other ECM components and characterized by the tissue structure reconstruction,in which the activation of hepatic stellate cells(HSCs)plays a pivotal role.Continuous clarification of molecular mechanisms has witnessed tremendous progress in the research and development of hepatic anti-fibrotic drugs covering hepatocyte protective agent,ECM synthesis and degradation modulator,HSCs activation and apoptosis modulator,anti-inflammatory agent and immunomodulator,and traditional Chinese medicine in treating hepatic fibrosis has also achieved some progress.更多还原